Antibiotic Lock Therapy for CRBSIs
Our Mino-Lok product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs). CRBSIs are very serious, especially in cancer patients receiving therapy through central venous catheters (CVCs) and in hemodialysis patients where venous access presents a challenge.
Address medical conditions that have unmet medical needs with cost-effective products.
Our Mino-Lok product is intended to salvage the CVC, obviating the need to remove and replace the catheter. This is a recognized unmet medical need. There are few alternatives to removing and replacing the CVC once it becomes infected. Studies show that removal and reinsertion of CVCs have a 15% to 20% complication rate, including pneumothorax, misplacement, and arterial puncture.
Our Mino-Lok product contains a proprietary combination of minocycline, edetate (disodium EDTA), and ethyl alcohol, all of which act synergistically to break down bacterial biofilms, eradicate the bacteria, provide anti-clotting properties to maintain patency in CVCs, and salvage the indwelling catheter. The Mino-Lok product is used in two-hour locking cycles, allowing the CVC to be used for its intended purposes for the remaining 22 hours each day.
[Bacterial growth environment]
After use of Mino-Lok
Our Mino-Lok product was developed by clinicians and technologists at the M.D. Anderson Cancer Center. Citius Pharmaceuticals obtained a worldwide license to the patented technology (with the exception of South America) in May 2014. In March 2016, Citius announced that it has a worldwide license for Mino-Lok.